The Covid-19 pandemic is a major threat to the public health and economies. Effective vaccines based on new technologies represent the main hope to stop it. Recent announcements on vaccine results are very promising however multiple vaccines are needed and the stability of vaccines as well as the apparent attenuation of the response due to the vector (adenoviral) or scaffold immune response may limit the efficiency of vaccination. A new vaccine platform invented by the group led by Prof Jerala, Head of Department of Synthetic Biology and Immunology addresses both issues.